Actas urologicas espanolas最新文献

英文中文

Coinfection of monkeypox, COVID-19 and syphilis in a PrEP using MSM: a case report from Barcelona 在使用 PrEP 的男男性行为者中同时感染猴痘、COVID-19 和梅毒：来自巴塞罗那的病例报告。

Actas urologicas espanolas

Pub Date : 2024-10-01 DOI: 10.1016/j.acuroe.2024.05.011

引用次数: 0

Gender trends at the annual Spanish Urologic Association (AEU) meeting: A review of AEU programmes over a 10-year period (2012–2022) 西班牙泌尿协会（AEU）年会的性别趋势：西班牙泌尿外科协会（AEU）年会的性别趋势：西班牙泌尿外科协会十年计划回顾（2012-2022 年）。

Actas urologicas espanolas

Pub Date : 2024-10-01 DOI: 10.1016/j.acuroe.2024.05.005

Introduction

Gender equity in urological meetings is pivotal for fostering diversity and inclusivity in the field. This study aims to evaluate the representation of Spanish urologist and regional disparities, and to assess its alignment with the demographic composition of the urological community.

Materials and methods

All urology meetings organized by the AEU between January 2012 and December 2022 were reviewed, including meeting information and details of the faculty. Additionally, we analysed geographic distribution of speakers across 17 different regions. Gender demographics were obtained disaggregating data by sex and year from the Organización Médica Colegial de España (OMC) and from those urologists affiliated to the AEU.

Results

Analysing 52 AEU congresses held from 2012 to 2022, encompassing 3,407 speakers, the study found that 95.25% of speakers were from Spain and 89.6% were male speakers. Over the years, there was a positive trend in female speaker representation, increasing by 1.1% annually, slightly lagging the 1.8% annual rise in the number of female urologists in Spain. In specific subfields like functional, transplantation, and oncology sessions, the study revealed a higher representation of women, indicating focused efforts in these areas. Geographically, Madrid, Catalonia and Andalusia exhibited the highest representation.

Conclusions

Although there was a positive trend towards an increased participation of female urologists in Spanish urological meetings, it fails to accurately reflect the proportional increase in the number of women entering the urology profession in recent years. This study underscores the importance of ongoing efforts to ensure diverse and balanced representation in urological forum.

导言：泌尿外科会议中的性别平等对于促进该领域的多样性和包容性至关重要。本研究旨在评估西班牙泌尿外科医生的代表性和地区差异，并评估其与泌尿外科界人口构成的一致性：我们回顾了 2012 年 1 月至 2022 年 12 月间由 AEU 组织的所有泌尿外科会议，包括会议信息和教师详情。此外，我们还分析了发言人在 17 个不同地区的地理分布情况。我们还从Organización Médica Colegial de España (OMC)和隶属于AEU的泌尿科医生那里获得了按性别和年份分列的性别人口统计数据：研究分析了2012年至2022年期间举行的52次AEU大会，共有3407人发言，发现95.25%的发言者来自西班牙，89.6%的发言者为男性。多年来，女性发言人的比例呈上升趋势，每年增加1.1%，略低于西班牙泌尿科女医生人数每年1.8%的增幅。研究显示，在功能、移植和肿瘤等特定子领域的会议上，女性代表的比例较高，这表明这些领域的工作重点是女性。从地域上看，马德里、加泰罗尼亚和安达卢西亚的女性比例最高：尽管西班牙泌尿外科会议中女性泌尿科医生的参与率呈上升趋势，但这并不能准确反映近年来进入泌尿外科行业的女性人数的增长比例。这项研究强调了持续努力确保泌尿外科论坛的多元化和均衡代表性的重要性。

{"title":"Gender trends at the annual Spanish Urologic Association (AEU) meeting: A review of AEU programmes over a 10-year period (2012–2022)","authors":"","doi":"10.1016/j.acuroe.2024.05.005","DOIUrl":"10.1016/j.acuroe.2024.05.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Gender equity in urological meetings is pivotal for fostering diversity and inclusivity in the field. This study aims to evaluate the representation of Spanish urologist and regional disparities, and to assess its alignment with the demographic composition of the urological community.</div></div><div><h3>Materials and methods</h3><div>All urology meetings organized by the AEU between January 2012 and December 2022 were reviewed, including meeting information and details of the faculty. Additionally, we analysed geographic distribution of speakers across 17 different regions. Gender demographics were obtained disaggregating data by sex and year from the Organización Médica Colegial de España (OMC) and from those urologists affiliated to the AEU.</div></div><div><h3>Results</h3><div>Analysing 52 AEU congresses held from 2012 to 2022, encompassing 3,407 speakers, the study found that 95.25% of speakers were from Spain and 89.6% were male speakers. Over the years, there was a positive trend in female speaker representation, increasing by 1.1% annually, slightly lagging the 1.8% annual rise in the number of female urologists in Spain. In specific subfields like functional, transplantation, and oncology sessions, the study revealed a higher representation of women, indicating focused efforts in these areas. Geographically, Madrid, Catalonia and Andalusia exhibited the highest representation.</div></div><div><h3>Conclusions</h3><div>Although there was a positive trend towards an increased participation of female urologists in Spanish urological meetings, it fails to accurately reflect the proportional increase in the number of women entering the urology profession in recent years. This study underscores the importance of ongoing efforts to ensure diverse and balanced representation in urological forum.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 8","pages":"Pages 574-580"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140913639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of DNA-Repair Gene mutations in Mexican men with prostate cancer 墨西哥男性前列腺癌患者 DNA 修复基因突变的发生率。

Actas urologicas espanolas

Pub Date : 2024-10-01 DOI: 10.1016/j.acuroe.2024.05.009

Introduction and objective

Mexico reported 26,742 new cases of prostate cancer in 2020. Different risk factors have been identified in the pathogenesis of prostate cancer. Among them, genetic factors and alterations or mutations in specific genes have been described in different ethnic groups worldwide. The aim of our study is to report the prevalence of germline DNA-repair gene mutations in Mexican patients with prostate cancer.

Material and method

We performed germline genetic testing in 50 patients with localized prostate cancer and 50 patients with metastatic prostate cancer. Demographic, clinical, and histopathological data were collected.

Results

Thirty-seven germline mutations were identified in 32 patients. The most commonly affected genes were ATM in 6%, followed by FANCA (5%), and ATR (4%). BRCA2 mutations were identified in 3%. The frequency of mutations was higher in the metastatic group.

Discussion and conclusion

The results of our study show different mutations from those reported in different populations or regions. The use of PARP inhibitors is indicated in patients with germline mutations, specifically BRCA2, showing improvement in overall survival and progression free survival. To our knowledge, this is the first study reporting the prevalence of mutations in DNA-repair genes in Mexican patients with prostate cancer.

导言和目标：据报告，2020 年墨西哥新增前列腺癌病例 26 742 例。在前列腺癌的发病机制中发现了不同的风险因素。其中，遗传因素和特定基因的改变或突变已在全球不同种族群体中得到描述。我们的研究旨在报告墨西哥前列腺癌患者种系 DNA 修复基因突变的发生率：我们对 50 名局部前列腺癌患者和 50 名转移性前列腺癌患者进行了种系基因检测。收集了人口统计学、临床和组织病理学数据：结果：在 32 名患者中发现了 37 个基因突变。最常受影响的基因是ATM，占6%，其次是FANCA（5%）和ATR（4%）。BRCA2基因突变占3%。在转移组中，基因突变的频率更高：我们的研究结果显示，不同人群或地区的突变情况有所不同。PARP抑制剂适用于有基因突变（尤其是BRCA2）的患者，可改善总生存期和无进展生存期。据我们所知，这是第一项报告墨西哥前列腺癌患者 DNA 修复基因突变发生率的研究。

{"title":"Prevalence of DNA-Repair Gene mutations in Mexican men with prostate cancer","authors":"","doi":"10.1016/j.acuroe.2024.05.009","DOIUrl":"10.1016/j.acuroe.2024.05.009","url":null,"abstract":"<div><h3>Introduction and objective</h3><div><span>Mexico reported 26,742 new cases of prostate cancer<span><span> in 2020. Different risk factors have been identified in the pathogenesis of prostate cancer. Among them, </span>genetic factors and alterations or mutations in specific genes have been described in different ethnic groups worldwide. The aim of our study is to report the prevalence of </span></span>germline DNA-repair gene mutations in Mexican patients with prostate cancer.</div></div><div><h3>Material and method</h3><div>We performed germline genetic testing in 50 patients with localized prostate cancer and 50 patients with metastatic prostate cancer. Demographic, clinical, and histopathological data were collected.</div></div><div><h3>Results</h3><div><span>Thirty-seven germline mutations were identified in 32 patients. The most commonly affected genes were </span><em>ATM</em> in 6%, followed by <span><em>FANCA</em></span> (5%), and <em>ATR</em> (4%). <span><span>BRCA2</span></span> mutations were identified in 3%. The frequency of mutations was higher in the metastatic group.</div></div><div><h3>Discussion and conclusion</h3><div><span>The results of our study show different mutations from those reported in different populations or regions. The use of PARP inhibitors<span> is indicated in patients with germline mutations, specifically BRCA2, showing improvement in </span></span>overall survival<span> and progression free survival. To our knowledge, this is the first study reporting the prevalence of mutations in DNA-repair genes in Mexican patients with prostate cancer.</span></div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 8","pages":"Pages 588-595"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140913626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The journey of determining PD-L1 expression in muscle-invasive urothelial carcinoma 确定浸润性尿路上皮癌中 PD-L1 的表达：西班牙解剖病理学会的建议。

Actas urologicas espanolas

Pub Date : 2024-10-01 DOI: 10.1016/j.acuroe.2024.05.015

引用次数: 0

Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer. 卡介苗供应标准化对非肌层浸润性膀胱癌患者治疗的影响共识文件。

Actas urologicas espanolas

Pub Date : 2024-09-26 DOI: 10.1016/j.acuroe.2024.09.005

Ó Rodríguez Faba, J M Fernández Gómez, F Guerrero-Ramos, M Álvarez-Maestro, M J Ledo Cepero, M Unda Urzaiz, L Martínez-Piñeiro, J M Cózar Olmo, J Palou Redorta, J L Álvarez-Ossorio

Patients with non-muscle-invasive bladder cancer (NMIBC) in the intermediate and high-risk groups must receive adjuvant treatment with intravesical Bacillus Calmette-Guérin (BCG) following transurethral resection (TUR), as it reduces the risk of recurrence and presumably the risk of progression as well. Optimization of BCG efficacy is achieved by administering maintenance therapy. However, since many immunological aspects of the mechanism of action of BCG in the bladder remain unknown, the implementation of the optimal dose, number of instillations, strains and adequate maintenance regimen over the last decades has been heterogeneous. Additionally, this has hindered the interpretation of efficacy in terms of oncologic outcomes. This, together with the shortages of BCG in recent years, have forced scientific societies to adapt their clinical practice guidelines and modify their protocols of adjuvant treatment with BCG. This includes changes to strains, doses, and maintenance during this period of time. This consensus document evaluates the current status of adjuvant BCG treatment and the implications of BCG supply availability in the treatment of patients with NMIBC. It also addresses the implementation of novel therapies that will improve cancer prognosis and the quality of life of patients with NMIBC in the future.

非肌层浸润性膀胱癌（NMIBC）中、高危组患者必须在经尿道切除术（TUR）后接受膀胱内卡介苗（BCG）辅助治疗，因为它能降低复发风险，并可能降低病情恶化的风险。卡介苗疗效的优化是通过维持治疗来实现的。然而，由于卡介苗在膀胱中作用机制的许多免疫学方面仍然未知，因此在过去几十年中，最佳剂量、注射次数、菌株和适当的维持治疗方案的实施情况各不相同。此外，这也妨碍了从肿瘤结果的角度解释疗效。再加上近年来卡介苗短缺，迫使科学协会调整临床实践指南，修改卡介苗辅助治疗方案。这包括在此期间对菌株、剂量和维持量的改变。本共识文件评估了卡介苗辅助治疗的现状以及卡介苗供应情况对治疗 NMIBC 患者的影响。它还讨论了未来将改善癌症预后和 NMIBC 患者生活质量的新型疗法的实施情况。

{"title":"Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer.","authors":"Ó Rodríguez Faba, J M Fernández Gómez, F Guerrero-Ramos, M Álvarez-Maestro, M J Ledo Cepero, M Unda Urzaiz, L Martínez-Piñeiro, J M Cózar Olmo, J Palou Redorta, J L Álvarez-Ossorio","doi":"10.1016/j.acuroe.2024.09.005","DOIUrl":"10.1016/j.acuroe.2024.09.005","url":null,"abstract":"<p><p>Patients with non-muscle-invasive bladder cancer (NMIBC) in the intermediate and high-risk groups must receive adjuvant treatment with intravesical Bacillus Calmette-Guérin (BCG) following transurethral resection (TUR), as it reduces the risk of recurrence and presumably the risk of progression as well. Optimization of BCG efficacy is achieved by administering maintenance therapy. However, since many immunological aspects of the mechanism of action of BCG in the bladder remain unknown, the implementation of the optimal dose, number of instillations, strains and adequate maintenance regimen over the last decades has been heterogeneous. Additionally, this has hindered the interpretation of efficacy in terms of oncologic outcomes. This, together with the shortages of BCG in recent years, have forced scientific societies to adapt their clinical practice guidelines and modify their protocols of adjuvant treatment with BCG. This includes changes to strains, doses, and maintenance during this period of time. This consensus document evaluates the current status of adjuvant BCG treatment and the implications of BCG supply availability in the treatment of patients with NMIBC. It also addresses the implementation of novel therapies that will improve cancer prognosis and the quality of life of patients with NMIBC in the future.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical application of the UroLift® prostatic urethral lift in Spain: consensus on the treatment of lower urinary tract symptoms associated with urinary flow obstruction and secondary to benign prostatic hyperplasia (BPH). UroLift® 前列腺尿道提升术在西班牙的临床应用：关于治疗与尿流梗阻相关并继发于良性前列腺增生症 (BPH) 的下尿路症状的共识。

Actas urologicas espanolas

Pub Date : 2024-09-23 DOI: 10.1016/j.acuroe.2024.09.004

M Fernández Arjona, L López Martín, L M Herranz Fernández, B Sinues Ojas, J M Campá Bortoló, J Extramiana Cameno, E López Alcina, I Povo Martín, A Budía Alba, G Ordaz Jurado, J M Osca García, M Perán Teruel, V Gimeno Argente, A Navarro Beltrán, J Benejam Gual, Y E Hernández Martínez, C González Enguita

Benign prostatic hyperplasia (BPH) is an increasingly common pathology in the adult male. BPH increases after the age of 40-45 years, and its management consumes an enormous amount of resources. The UroLift® System is an approved technology designed to treat lower urinary tract symptoms (LUTS) secondary to BPH and is used to perform the prostatic urethral lift (PUL) procedure. Various urology specialists in Spain with experience in PUL have prepared this consensus document. Endorsed by the Spanish Urology Association, its information is based on the most recent findings. The main objective of this document is to disseminate the consensus recommendations among all professionals treating patients with LUTS/BPH. Both primary care physicians and urologists can assess and offer PUL as an effective, minimally invasive treatment.

良性前列腺增生症（BPH）在成年男性中越来越常见。良性前列腺增生症患者在 40-45 岁后逐渐增多，其治疗耗费了大量资源。UroLift® 系统是一项已获批准的技术，用于治疗继发性良性前列腺增生症（BPH）引起的下尿路症状（LUTS），并可用于实施前列腺尿道提升术（PUL）。西班牙多位具有前列腺尿道上提术经验的泌尿科专家编写了这份共识文件。本文件由西班牙泌尿外科协会批准，其信息以最新研究成果为基础。本文件的主要目的是向所有治疗 LUTS/BPH 患者的专业人员传播共识建议。初级保健医生和泌尿科医生都可以将 PUL 作为一种有效的微创治疗方法进行评估和提供。

{"title":"Clinical application of the UroLift® prostatic urethral lift in Spain: consensus on the treatment of lower urinary tract symptoms associated with urinary flow obstruction and secondary to benign prostatic hyperplasia (BPH).","authors":"M Fernández Arjona, L López Martín, L M Herranz Fernández, B Sinues Ojas, J M Campá Bortoló, J Extramiana Cameno, E López Alcina, I Povo Martín, A Budía Alba, G Ordaz Jurado, J M Osca García, M Perán Teruel, V Gimeno Argente, A Navarro Beltrán, J Benejam Gual, Y E Hernández Martínez, C González Enguita","doi":"10.1016/j.acuroe.2024.09.004","DOIUrl":"10.1016/j.acuroe.2024.09.004","url":null,"abstract":"<p><p>Benign prostatic hyperplasia (BPH) is an increasingly common pathology in the adult male. BPH increases after the age of 40-45 years, and its management consumes an enormous amount of resources. The UroLift® System is an approved technology designed to treat lower urinary tract symptoms (LUTS) secondary to BPH and is used to perform the prostatic urethral lift (PUL) procedure. Various urology specialists in Spain with experience in PUL have prepared this consensus document. Endorsed by the Spanish Urology Association, its information is based on the most recent findings. The main objective of this document is to disseminate the consensus recommendations among all professionals treating patients with LUTS/BPH. Both primary care physicians and urologists can assess and offer PUL as an effective, minimally invasive treatment.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of changes in sexual function in patients undergoing endoscopic surgery for upper urinary tract lithiasis. 评估接受内窥镜手术治疗上尿路结石患者的性功能变化。

Actas urologicas espanolas

Pub Date : 2024-09-21 DOI: 10.1016/j.acuroe.2024.09.003

J Tabares Jiménez, G Bueno Serrano, M P Alcoba García, R González López, B Gómez Jordana, I Mahillo Fernández, C González Enguita

Objective: To evaluate the effect of endoscopic surgery on sexual function in patients with upper urinary tract (UUT) lithiasis.

Material and methods: We conducted an observational, prospective, longitudinal study with a single cohort of cases undergoing ureteroscopy (URS), retrograde intrarenal surgery (RIRS), or endoscopic combined intrarenal surgery (ECIRS). Patients' sexual response was assessed with questionnaires in the 30 days prior to surgery, and at one and three months after surgery. The International Index of Erectile Function (IIEF-t) was used in male patients, and the Female Sexual Function Index (FSFI) was used in female patients.

Results: Seventy patients - 34 men and 36 women - completed the study. Among men, the IIEF-t did not show significant difference between baseline scores (64.1 ± 7.50) and those obtained at 3 months (63.8 ± 9.51), with a non-significant decrease (p = 0.054) at the first month (61.4 ± 10.4). Subdomains did not worsen at 3 months, and desire (IIEF-SD) improved from 7.3 ± 1.9 to 8.0 ± 1.8. Among women, the FSFI-t did not change significantly after surgery: baseline score (27.3 ± 4.1), 1-month score (26.8 ± 3.7) and 3-month score (27.5 ± 4.2). No subdomain worsened at the third month.

Conclusion: Endoscopic surgery for UUT is a safe technique in both sexes with no negative effect on sexual function. There are no differences between the baseline IIEF-t and FSFI-t scores and those obtained at 3 months.

目的：评估内窥镜手术对上尿路结石（UUT）患者性功能的影响：评估内窥镜手术对上尿路（UUT）结石患者性功能的影响：我们对接受输尿管镜检查（URS）、逆行肾内手术（RIRS）或内镜联合肾内手术（ECIRS）的病例进行了一项观察性、前瞻性、纵向研究。在手术前30天、手术后1个月和3个月，对患者的性反应进行了问卷评估。男性患者采用国际勃起功能指数（IIEF-t），女性患者采用女性性功能指数（FSFI）：共有 70 名患者完成了研究，其中男性 34 人，女性 36 人。在男性患者中，IIEF-t 的基线分数（64.1 ± 7.50）与 3 个月后的分数（63.8 ± 9.51）之间没有明显差异，第一个月的分数（61.4 ± 10.4）下降不明显（p = 0.054）。3 个月后，子域的情况没有恶化，欲望（IIEF-SD）从 7.3 ± 1.9 改善到 8.0 ± 1.8。在女性中，FSFI-t 在术后没有明显变化：基线分数（27.3 ± 4.1）、1 个月分数（26.8 ± 3.7）和 3 个月分数（27.5 ± 4.2）。结论：内窥镜手术治疗 UUT 是一种有效的方法：结论：内窥镜手术治疗 UUT 是一种安全的技术，对男女性功能均无负面影响。基线IIEF-t和FSFI-t评分与3个月时的评分没有差异。

{"title":"Assessment of changes in sexual function in patients undergoing endoscopic surgery for upper urinary tract lithiasis.","authors":"J Tabares Jiménez, G Bueno Serrano, M P Alcoba García, R González López, B Gómez Jordana, I Mahillo Fernández, C González Enguita","doi":"10.1016/j.acuroe.2024.09.003","DOIUrl":"10.1016/j.acuroe.2024.09.003","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effect of endoscopic surgery on sexual function in patients with upper urinary tract (UUT) lithiasis.</p><p><strong>Material and methods: </strong>We conducted an observational, prospective, longitudinal study with a single cohort of cases undergoing ureteroscopy (URS), retrograde intrarenal surgery (RIRS), or endoscopic combined intrarenal surgery (ECIRS). Patients' sexual response was assessed with questionnaires in the 30 days prior to surgery, and at one and three months after surgery. The International Index of Erectile Function (IIEF-t) was used in male patients, and the Female Sexual Function Index (FSFI) was used in female patients.</p><p><strong>Results: </strong>Seventy patients - 34 men and 36 women - completed the study. Among men, the IIEF-t did not show significant difference between baseline scores (64.1 ± 7.50) and those obtained at 3 months (63.8 ± 9.51), with a non-significant decrease (p = 0.054) at the first month (61.4 ± 10.4). Subdomains did not worsen at 3 months, and desire (IIEF-SD) improved from 7.3 ± 1.9 to 8.0 ± 1.8. Among women, the FSFI-t did not change significantly after surgery: baseline score (27.3 ± 4.1), 1-month score (26.8 ± 3.7) and 3-month score (27.5 ± 4.2). No subdomain worsened at the third month.</p><p><strong>Conclusion: </strong>Endoscopic surgery for UUT is a safe technique in both sexes with no negative effect on sexual function. There are no differences between the baseline IIEF-t and FSFI-t scores and those obtained at 3 months.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Scientific research productivity in urology: A 20-year bibliometric analysis in Latin America. 泌尿外科的科研生产力：拉丁美洲 20 年文献计量分析。

Actas urologicas espanolas

Pub Date : 2024-09-21 DOI: 10.1016/j.acuroe.2024.09.002

G Mendoza-Chuctaya, K Rodrigo-Ramos, P Mendoza-Arana, E Rios-Cadenillas

Introduction and objectives: The knowledge generated by scientific research is linked to the development of countries, as it provides the necessary resources to guarantee scientific progress and cost-effective healthcare. For this reason, our study analyzes the trends of scientific publication in urology in Latin America.

Methods: A bibliometric analysis was performed. Data collection was carried out using the SCOPUS search engine in April 2023, and the search terms were defined by the authors, including the most common diseases in the specialty of urology. A descriptive analysis of the different characteristics, trends and scientific collaborations was performed. The collaboration networks were plotted using VOSviewer.

Results: From 2000 to 2021, Latin American publications in urology amounted to 9135 in scientific journals. Brazil is the country with the greatest scientific production (51.2%) and Chile has the greatest scientific production per million inhabitants. Of the total number of scientific publications, 51.1% were related to prostate cancer, 88.8% were written in English (and 50.2% had non-open access). The country with greatest collaborative research with Latin America was the United States.

Conclusions: Scientific output in urology in Latin America has increased substantially over the last 20 years. The most published topic is prostate cancer, most papers are written in English, and the United States takes first place regarding scientific collaboration. However, the proportion of the world's science originated in Latin America is still low and depends on Brazil.

导言和目标：科学研究产生的知识与国家的发展息息相关，因为它为保证科学进步和具有成本效益的医疗保健提供了必要的资源。为此，我们的研究分析了拉丁美洲泌尿科科学出版物的发展趋势：方法：进行文献计量分析。数据收集是在 2023 年 4 月使用 SCOPUS 搜索引擎进行的，检索词由作者定义，包括泌尿外科专业中最常见的疾病。对不同的特征、趋势和科研合作进行了描述性分析。使用 VOSviewer 绘制了合作网络图：从 2000 年到 2021 年，拉丁美洲在科学杂志上发表的泌尿外科论文达 9135 篇。巴西是科研成果最多的国家（51.2%），智利是每百万人口科研成果最多的国家。在所有科学出版物中，51.1%与前列腺癌有关，88.8%用英语撰写（50.2%为非开放获取）。与拉丁美洲开展合作研究最多的国家是美国：结论：在过去 20 年中，拉丁美洲泌尿科的科研成果大幅增加。发表论文最多的主题是前列腺癌，大多数论文都是用英语撰写的，在科研合作方面，美国居首位。然而，拉丁美洲的科学成果在世界科学成果中所占比例仍然很低，而且主要依赖于巴西。

{"title":"Scientific research productivity in urology: A 20-year bibliometric analysis in Latin America.","authors":"G Mendoza-Chuctaya, K Rodrigo-Ramos, P Mendoza-Arana, E Rios-Cadenillas","doi":"10.1016/j.acuroe.2024.09.002","DOIUrl":"10.1016/j.acuroe.2024.09.002","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>The knowledge generated by scientific research is linked to the development of countries, as it provides the necessary resources to guarantee scientific progress and cost-effective healthcare. For this reason, our study analyzes the trends of scientific publication in urology in Latin America.</p><p><strong>Methods: </strong>A bibliometric analysis was performed. Data collection was carried out using the SCOPUS search engine in April 2023, and the search terms were defined by the authors, including the most common diseases in the specialty of urology. A descriptive analysis of the different characteristics, trends and scientific collaborations was performed. The collaboration networks were plotted using VOSviewer.</p><p><strong>Results: </strong>From 2000 to 2021, Latin American publications in urology amounted to 9135 in scientific journals. Brazil is the country with the greatest scientific production (51.2%) and Chile has the greatest scientific production per million inhabitants. Of the total number of scientific publications, 51.1% were related to prostate cancer, 88.8% were written in English (and 50.2% had non-open access). The country with greatest collaborative research with Latin America was the United States.</p><p><strong>Conclusions: </strong>Scientific output in urology in Latin America has increased substantially over the last 20 years. The most published topic is prostate cancer, most papers are written in English, and the United States takes first place regarding scientific collaboration. However, the proportion of the world's science originated in Latin America is still low and depends on Brazil.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Why do patients with urinary diversions have an increased risk of bone fracture? A systematic review on risk factors for osteoporosis and bone mineral density loss in this group of patients 为什么尿路改道患者发生骨折的风险会增加？关于该类患者骨质疏松症和骨矿物质密度损失风险因素的系统综述。

Actas urologicas espanolas

Pub Date : 2024-09-01 DOI: 10.1016/j.acuroe.2023.11.009

Introduction

Patients undergoing radical cystectomy with urinary diversions (UD) are at increased risk of bone fractures compared to the general population. Although a loss of bone mineral density (BMD) has been described in patients with UD, we still do not know with certainty why these patients follow this tendency.

Objective

We performed a systematic review of the available literature to analyze the prevalence of osteoporosis and bone alterations in patients with ileal UD and the possible associated risk factors.

Evidence acquisition

We systematically searched PubMed® and Cochrane Library for original articles published before December 2022 according to PRISMA guidelines.

Evidence synthesis

A total of 394 publications were identified. We selected 12 studies that met the inclusion criteria with 496 patients included. Six of the twelve studies showed decreased BMD values. Prevalence of osteoporosis was specified in three articles, with values ranging from 0% to 36%. Risk factors such as age, sex, body mass index, metabolic acidosis and renal function appear to have an impact on bone tissue reduction, while type of UD, follow-up, 25-hydroxyvitamin D and parathormone had less evidence or contradictory data. The heterogeneity of the studies analyzed could led to interpretation bias.

Conclusions

UD are associated with multiple risk factors for osteoporosis and bone fractures. Identifying patients at highest risk and establishing diagnostic protocols in routine clinical practice are essential to reduce the risk of fractures and the resulting complications.

简介：与普通人群相比，接受根治性膀胱切除术和尿路改道手术（UDs）的患者发生骨折的风险更高。虽然已有文献描述尿路转流术患者的骨矿物质密度（BMD）会下降，但我们仍不清楚这些患者为何会出现这种趋势：我们对现有文献进行了系统回顾，以分析回肠 UD 患者骨质疏松症和骨质改变的患病率以及可能的相关风险因素：根据 PRISMA 指南，我们系统检索了 PubMed® 和 Cochrane 图书馆中 2022 年 12 月之前发表的原创文章：共发现 394 篇文献。我们选择了符合纳入标准的 12 项研究，共纳入 496 名患者。12 项研究中有 6 项显示 BMD 值下降。有三篇文章明确指出了骨质疏松症的患病率，数值从 0% 到 36% 不等。年龄、性别、体重指数、代谢性酸中毒和肾功能等风险因素似乎对骨组织减少有影响，而尿失禁类型、随访、25-羟维生素 D 和副肾激素的证据较少或数据相互矛盾。所分析研究的异质性可能会导致解释偏差：UD与骨质疏松症和骨折的多种风险因素相关。识别高危患者并在常规临床实践中制定诊断方案对于降低骨折风险及由此引发的并发症至关重要。

{"title":"Why do patients with urinary diversions have an increased risk of bone fracture? A systematic review on risk factors for osteoporosis and bone mineral density loss in this group of patients","authors":"","doi":"10.1016/j.acuroe.2023.11.009","DOIUrl":"10.1016/j.acuroe.2023.11.009","url":null,"abstract":"<div><h3>Introduction</h3><p><span>Patients undergoing radical cystectomy with </span>urinary diversions (UD) are at increased risk of bone fractures compared to the general population. Although a loss of bone mineral density (BMD) has been described in patients with UD, we still do not know with certainty why these patients follow this tendency.</p></div><div><h3>Objective</h3><p><span>We performed a systematic review<span> of the available literature to analyze the prevalence of osteoporosis and bone alterations in patients with ileal UD and the possible associated </span></span>risk factors.</p></div><div><h3>Evidence acquisition</h3><p>We systematically searched PubMed® and Cochrane Library for original articles published before December 2022 according to PRISMA guidelines.</p></div><div><h3>Evidence synthesis</h3><p><span>A total of 394 publications were identified. We selected 12 studies that met the inclusion criteria with 496 patients included. Six of the twelve studies showed decreased BMD values. Prevalence of osteoporosis was specified in three articles, with values ranging from 0% to 36%. Risk factors such as age, sex, body mass index, </span>metabolic acidosis<span><span> and renal function<span> appear to have an impact on bone tissue reduction, while type of UD, follow-up, 25-hydroxyvitamin D and </span></span>parathormone had less evidence or contradictory data. The heterogeneity of the studies analyzed could led to interpretation bias.</span></p></div><div><h3>Conclusions</h3><p>UD are associated with multiple risk factors for osteoporosis and bone fractures. Identifying patients at highest risk and establishing diagnostic protocols in routine clinical practice are essential to reduce the risk of fractures and the resulting complications.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 7","pages":"Pages 497-511"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139748039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Why is it necessary to produce a BCG strain in Spain? 为什么必须在西班牙生产卡介苗菌株？

Actas urologicas espanolas

Pub Date : 2024-09-01 DOI: 10.1016/j.acuroe.2024.04.003

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Actas urologicas espanolas

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀